GRENOBLE, France, March 31, 2016 /PRNewswire/ -- ImmunID, the immune companion diagnostics for precision medicine company, today announces that a collaborative work on prediction of response to the anti-PD1 and anti-CTLA-4 immune checkpoint inhibitors in melanoma using ImmunTraCkeR® has been selected for a poster presentation during the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3-7, 2016. These results were generated in collaboration with Zurich University Hospital (Switzerland) and the NKI (The Netherlands), two leading European clinical centers in Immuno-Oncology.
"We are honored that the ASCO Scientific Program Committee has selected this collaborative work describing the use of the ImmunTraCkeR® assay for prediction of response to the immune checkpoint cancer immunotherapy," said Dr Nicolas Pasqual, Co-Founder and Chief Scientific Officer of ImmunID. "We are looking forward to sharing updated ImmunTraCkeR® data in this prestigious scientific forum, and to discussing the data and our future development plans with key immuno-oncology scientific and clinical experts during the ASCO meeting" added Dr Bernhard Sixt, ImmunID's Chairman and Chief Executive Officer.
With over 30,000 attendees, the ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO's Annual Meeting represent the extent of progress made each year in the fight against cancer. To learn more about the ASCO Annual meeting: http://am.asco.org/
ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provides doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID's flagship CE-marked product, ImmunTraCkeR®, evaluates the patient's immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.
www.immunid.com - Follow ImmunID on Twitter: @ImmunID
ImmunTraCkeR® is a proprietary CE-marked immune molecular diagnostics assay, which evaluates a patient's immune status in the blood based on combinatorial T cell diversity. Unlike most companion diagnostics tests, ImmunTraCkeR® is patient-specific rather than drug- or disease-specific, as it approaches the disease from the patient's own immune system perspective. ImmunTraCkeR® provides information on the patient's complex immune profile to evaluate clinical benefit or risk under treatment with immunotherapies. ImmunTraCkeR® may ultimately be used as immune companion diagnostics and answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.
Dr. Bernhard Sixt
Chairman and CEO
Phone: +33 438 785 770
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immuntracker-results-on-prediction-of-response-to-cancer-immunotherapy-selected-for-presentation-at-asco-annual-meeting-300243957.html